Paclitaxel-based combination chemotherapy for breast cancer

ONCOLOGY

Volumn 11, Issue 3 SUPPL. 2, 1997, Pages 29-37

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; EDATREXATE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; MEGESTROL ACETATE; MITOXANTRONE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; VALSPODAR; VERAPAMIL;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; PACLITAXEL;

EID: 0030947405     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-805, 1991.
2. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, G et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12(12):2654-2666, 1994.
3. Seidman AD, Hudis CA, Fennelly D, et al: Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer (review). Semin Oncol 22(suppl 12):108-116, 1995.
4. Seidman AD, Reichman BS, Crown JP, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer. Activity independent of prior anthracycline response. J Clin Oncol 13(5):1152-1159, 1995.
5. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12(8):1621-1629, 1994.
6. Gelmon KA: Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Semin Oncol 22(suppl 12):117-122, 1995.
7. Dieras V, Marty M, Morvan F, et al: A phase II randomized study of taxol versus mitomycin c in patients with advanced breast cancer: Interim analysis (abstract 1683). Proc Am Soc Clin Oncol 13:112, 1994.
8. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel (Taxol) activity in heavily treated metastatic breast cancer (abstract 494). Ann Oncol 5(suppl 5):199, 1994.
9. Fisherman JS, McCabe M, Noone M, et al: Phase I sludy of taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. Natl Cancer Inst Monogr 189 15, 1993.
10. Holmes FA, Newman RA, Madden T, et al: Schedule dependent pharmacokinetics in a phase I trial of taxol and doxorubicin as initial chemotherapy for metastatic breast cancer (abstract 489). Ann Oncol 5(suppl 5):197, 1994.
11. Holmes FA: Update: The M. D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. Semin Oncol 22;(suppl 8):9-15, 1995.
12. O'Shaughnessy JA, Fisherman JS, Cowan KH: Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer (review). Semin Oncol 21(suppl 8):19-23, 1994.
13. Holmes FA, Frye D, Valero V, et al: Phase I sludy of taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer (abstract 66). Proc Am Soc Clin Oncol 11:60, 1992.
14. Sledge G, Sparano J, McCaskill-Stevens W, et al: Pilot trial of alternating taxol and adriamycin for metastatic breast cancer (abstract 85). Proc Am Soc Clin Oncol 12:71, 1993.
15. Sledge GW Jr: Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 22(suppl 12):123-125, 1995.
16. Sledge GW Jr, Robert N, Sparano JA, et al: Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer (review). Semin Oncol 22(suppl 6):105-108, 1995.
17. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13(11):2688-2699, 1995.
18. Gehl J, Ejlersen M, Boesgaard M, et al: Efficacy and toxicity of combined doxorubicin and paclitaxel in metastatic breast cancer (preliminary results) (abstract 192). Ann Oncol 5:39, 1995.
19. Sledge GW, Jr: Cisplatin and platinum analogues in breast cancer (review). Semin Oncol 19(suppl 2):78-82, 1992.
20. Gelmon KA, O'Reilly SE, Tolcher AW, et al: Phase 1/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 14(4):1185-1191, 1996.
21. Wasserheit C, Frazein A, Oratz R, et al: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity. J Clin Oncol 14(7):1993-1199, 1996.
22. Kennedy MJ, Zahurak ML, Donehower RC, et al: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14(3):783-791, 1996.
23. Tolcher AW, Cowan KH, Noone MH, et al: Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14(1):95-102, 1996.
24. Cagnoni PJ, Stemmer SM, Matthes S, et al: Phase I trial of high dose paclitaxel (taxol), cyclophosphamide and cisplatin with autologous hematopoietic progenitor cell rescue (abstract 1548). Proc Am Soc Clin Oncol 14:477, 1995.
25. Pagani O, Sessa C, Goldhirsch A, et al: Taxol and cyclophosphamide in patients with advanced breast cancer: A dose-finding study with the addition of G-CSF (abstract 45). Proc Am Soc Clin Oncol 13:61, 1994.
26. Johnson SA, Harper P, Hortobagyi GN, et al: Vinorelbine: An overview. Cancer Treat Rev 22:127-142, 1996.
27. Adams DJ: Synergy of navelbine-taxol combination treatment in two human breast cancer cell lines (abstract 1944). Proc Am Assoc Cancer Res 35:327, 1994.
28. Ibrahim N, Hortobagyi GN, Valero V, et al: Phase I study of vinorelbine (navelbine) and paclitaxel by simultaneous 3-hour infusion for untreated metastatic breast cancer (abstract 1443). Proc Am Assoc Cancer Res 36:242, 1995.
29. Ibrahim NK, Hortobagyi GN, Valero V, et al: Phase T study of vinorelbine (navelbine) and paclitaxel (taxol) by simultaneous 3-hour infusion with G-CSF support, for untreated metastatic breast cancer (abstract 107). Breast Cancer Res Treat 37:(suppl 44), 1996.
30. Conte PF, Michelotti A, Baldini E, et al: A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer. Semin Oncol 23(suppl 11):28-31, 1996.
31. Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 22(suppl 5):66-70, 1995.
32. Dittrich C, Zifko U, Fazeny B, et al: Vinorelbine after paclitaxel in breast cancer: Cross resistance and cumulative neurotoxicity? (letter). Ann Oncol 5(5):473-474, 1994.
33. Paul DM, Garrett AM, Meshad M, et al: Paclitaxel and 5-fluorouracil in metastatic breast cancer: The US experience. Semin Oncol 23(suppl 1):48-52, 1996.
34. Klaassen U, Wilke H, Philippou Pari C, et al: Phase I/II study with paclitaxel in combination with weekly high dose 5-FU/folinic acid in the treatment of metastatic breast cancer (abstract 186). Proc Am Soc Clin Oncol 14:122, 1995.
35. Madajewicz S, LiPera W, Pendyala L, et al: Phase I study of 96 hours continuous intravenous infusion (CI) of Taxol followed by 24 hours CI of 5-fluorouracil and folinic acid (abstract 1589). Proc Am Soc Clin Oncol 14:487, 1995.
36. Cobb P, Burris H, Peacock N, et al: Phase I trial of losoxantrone plus paclitaxel given every 21 days (abstract 1545). Proc Am Soc Clin Oncol 14:476, 1995.
37. Fennelly D, Gilewski T, Hudis C, et al: Phase I trial of sequential edatrexate followed by paclitaxel: A design based on in vitro synergy in patients with advanced breast cancer (abstract 105). Proc Am Soc Clin Oncol 14:101, 1995.
38. Raptis G, Tiersten A, Hamilton N, et al: Outpatient based, rapidly administered multi-cycle high dose chemotherapy in patients with responding metastatic breast cancer (abstract 920). Proc Am Soc Clin Oncol 14:314, 1995.
39. 3 4(+) lymph nodes (abstract 62). Proc Am Soc Clin Oncol 13:65, 1994.
40. Seidman AD, Hudis CA, Norton L: Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: From advanced disease to adjuvant therapy Semin Oncol 22(suppl 8):3-8, 1995.
41. Demetri GD, Berry D, Younger J, et al: Dose-intensified cyclophosphamide/doxorubicin followed by Taxol as adjuvant systemic chemotherapy for node-positive breast cancer (CALGB 9141): Randomized comparison of two dose levels of G-CSF (abstract 63). Proc Am Soc Clin Oncol 13:65, 1994.
42. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive nodes. J Clin Oncol 9:2134-2140, 1991.
43. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results [see comments]. JAMA 273(7):542-547, 1995.
44. Capri G, Tarenzi E, Bertuzzi A, et al: Paclitaxel by 3-hour infusion and bolus doxorubicin on day 1 & 8 every three-weeks in women with metastatic breast cancer (abstract 850). Ann Oncol 7:(suppl 5)20, 1996.
45. Dombernowsky P, Gehl J, Boesgaard M, et al: Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23:(5)(suppl 11):23-7, 1996.
46. Frassineti GL, Zoli W, Tienghi A, et al: Phase I/II study of sequential combination of paclitaxel and doxorubicin in the treatment of advanced breast cancer (abstract 103). Proc Am Soc Clin Oncol 15:109, 1996.
47. Schwartsmann G, Menke CH, Caleffi M, et al: Phase II trial of Taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer (abstract 168). Proc Am Soc Clin Oncol 15:126, 1996.
48. Cazap E, Ventriglia M, Rubio G, et al: Taxol plus doxorubicin the treatment of metastatic breast cancer (abstract 248). Proc Am Soc Clin Oncol 15:146, 1996.
49. Catimel G, Spielmann M, Dieras V, et al: Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety. Semin Oncol 23(suppl 1):24-7, 1996.
50. Luck HJ, Thomssen C, duBois A, et al: Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 23(suppl 1):33-6, 1996.
51. Di Costanzo F, Sdrobolini A, Bilancia D, et al: Phase I-II trial of mitoxantrone and taxol in advanced breast cancer (abstract 220). Proc Am Soc Clin Oncol 15:139, 1996.
52. Browne MJ, Kennedy T, Cummings F, et al: Phase II study of sequential taxol and cisplatin for the treatment of metastatic breast cancer (abstract 245). Proc Am Soc Clin Oncol 14:136, 1995.
53. Berry J, Ezzat A, El-Warith A, et al: Sequential Taxol/platinum: Pilot study in metastatic breast cancer (abstract 243). Proc Am Soc Clin Oncol 14:136, 1995.
54. Chollet P, Charrier S, Brain E, et al: Neo-adjuvant chemotherapy in breast cancer: High pathological response rate induced by intensive anthracyclin-based regimen (abstract 218). Proc Am Soc Clin Oncol 14:130, 1995.